Pds Biotechnology Corp Stock Alpha and Beta Analysis
| PDSB Stock | USD 1.23 0.03 2.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as PDS Biotechnology Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in PDS Biotechnology over a specified time horizon. Remember, high PDS Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to PDS Biotechnology's market risk premium analysis include:
Beta 0.74 | Alpha (0.41) | Risk 6.31 | Sharpe Ratio (0.09) | Expected Return (0.57) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
PDS |
PDS Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. PDS Biotechnology market risk premium is the additional return an investor will receive from holding PDS Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PDS Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate PDS Biotechnology's performance over market.| α | -0.41 | β | 0.74 |
PDS Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of PDS Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how PDS Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.PDS Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how PDS Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PDS Biotechnology shares will generate the highest return on investment. By understating and applying PDS Biotechnology stock market price indicators, traders can identify PDS Biotechnology position entry and exit signals to maximize returns.
PDS Biotechnology Return and Market Media
The median price of PDS Biotechnology for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 1.54 with a coefficient of variation of 15.79. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 1.56, and mean deviation of 0.2. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Iliev Ilian of 9000 shares of PDS Biotechnology at 3.9 subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Glover Steve C of 9000 shares of PDS Biotechnology at 1.45 subject to Rule 16b-3 | 01/17/2025 |
3 | PDS Biotech to Participate at B. Riley Securities Precision Oncology Radiopharma ... | 02/20/2025 |
4 | Acquisition by Glover Steve C of 9000 shares of PDS Biotechnology at 9.95 subject to Rule 16b-3 | 02/21/2025 |
5 | PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial Published in Clinical Cancer Research | 02/24/2025 |
6 | PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical ... | 02/26/2025 |
7 | HC Wainwright Reiterates Buy Rating for PDS Biotechnology | 02/27/2025 |
8 | Acquisition by Glover Stephen C. of 15061 shares of PDS Biotechnology at 1.53 subject to Rule 16b-3 | 02/28/2025 |
9 | Acquisition by Glover Stephen C. of 15061 shares of PDS Biotechnology at 1.66 subject to Rule 16b-3 | 03/03/2025 |
10 | Insider Buying Stephen Glover Acquires Additional Shares of PDS Biotechnology Corp | 03/04/2025 |
11 | Acquisition by Sykes Richard of 9000 shares of PDS Biotechnology at 2.86 subject to Rule 16b-3 | 03/07/2025 |
12 | Synaptics Extends Edge AI Portfolio with High-Performance AdaptiveMCUs for Multimodal Context-Aware Computing | 03/10/2025 |
13 | PDS Biotech Announces FDA Clearance of IND Application for Combi | 03/13/2025 |
About PDS Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including PDS or other stocks. Alpha measures the amount that position in PDS Biotechnology Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
PDS Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of PDS Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PDS Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of PDS Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of PDS Biotechnology. Please utilize our Beneish M Score to check the likelihood of PDS Biotechnology's management manipulating its earnings.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with PDS Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out PDS Biotechnology Backtesting, PDS Biotechnology Valuation, PDS Biotechnology Correlation, PDS Biotechnology Hype Analysis, PDS Biotechnology Volatility, PDS Biotechnology History and analyze PDS Biotechnology Performance. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
PDS Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.